T2 Biosystems (TTOO)
(Delayed Data from NSDQ)
$2.19 USD
-0.01 (-0.45%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.28 +0.09 (4.11%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TTOO 2.19 -0.01(-0.45%)
Will TTOO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TTOO based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for TTOO
T2 Biosystems Achieves Successful Defense of Patent for Direct-From-Whole Blood Pathogen Detection Method in the European Union
T2 Biosystems achieves successful defense against key patent
T2 Biosystems Receives FDA Clearance to Market the T2Candida Panel for Pediatric Patients
T2 Biosystems Gains FDA Nod for Pediatric Sepsis Test
T2 Biosystems receives FDA clearance to market the T2Candida Panel